Plasma biomarkers offer a minimally invasive, accessible alternative to CSF biomarkers for the antemortem diagnosis and pathological classification of corticobasal syndrome (CBS). Recent advances in ultrasensitive assay technologies have enabled reliable detection of neurodegeneration-related proteins in blood, making plasma biomarkers increasingly important for clinical practice and research. [@plasma2024]
Key Plasma Biomarker Categories
Tau Protein Biomarkers
...
Plasma Biomarkers for Corticobasal Syndrome and Progressive Supranuclear Palsy
Overview
Mermaid diagram (expand to render)
Plasma biomarkers offer a minimally invasive, accessible alternative to CSF biomarkers for the antemortem diagnosis and pathological classification of corticobasal syndrome (CBS). Recent advances in ultrasensitive assay technologies have enabled reliable detection of neurodegeneration-related proteins in blood, making plasma biomarkers increasingly important for clinical practice and research. [@plasma2024]
Key Plasma Biomarker Categories
Tau Protein Biomarkers
Phosphorylated Tau (p-tau)
p-tau217 [@plasma2024a]
Shows exceptional sensitivity for detecting AD pathology
Can distinguish CBS-AD from CBS due to primary tauopathies
Higher diagnostic accuracy than p-tau181 in head-to-head comparisons
Correlates with cortical tau burden on PET
p-tau181 [@neurofilament2024]
Most extensively validated plasma biomarker
Elevated in CBS patients with AD co-pathology
Can differentiate PSP from CBS in some studies, though with limited specificity
p-tau231 [@bloodbased2024]
May be more specific for AD pathology in early disease stages
Lower levels in PSP compared to CBS-AD
p-tau205 [@plasma2024b]
Emerging marker with potential for tauopathy differentiation
Total Tau
Less specific than p-tau variants
Elevated in advanced disease stages
Correlates with overall neurodegeneration severity
β-Amyloid Biomarkers
Aβ42/Aβ40 Ratio
Plasma ratio mirrors CSF findings with good accuracy
Reduced ratio predicts AD pathology in CBS patients
Important for treatment stratification (anti-amyloid therapy eligibility)
Requires careful preanalytical handling
Aβ40 and Aβ42 Absolute Levels
Both typically reduced in presence of amyloid pathology
Ratio more reliable than absolute levels
Neurodegeneration Markers
Neurofilament Light Chain (NfL)
Highly sensitive marker for axonal damage
Elevated in both CBS and PSP compared to controls
Correlates with disease severity and progression rate
Useful for monitoring disease progression in clinical trials
Not specific to underlying pathology
Neurofilament Heavy Chain (pNfH)
More specific for cortical neurodegeneration
Correlates with cortical atrophy measures
Higher levels associated with more rapid progression
Glial Fibrillary Acidic Protein (GFAP)
Marker of astrocyte activation
Elevated in neurodegenerative conditions
May help differentiate CBS from other parkinsonian disorders
α-Synuclein Biomarkers
Seed Amplification Assays (SAA)
RT-QuIC and PMCA can detect pathological α-synuclein in plasma
Positive in CBS cases with Lewy body pathology
Specificity challenges remain
Plasma Total α-Synuclein
Generally lower in CBS with Lewy body pathology
Less reliable than CSF measurements
Clinical Applications
Differential Diagnosis
Plasma biomarkers assist in distinguishing:
CBS from PSP (overlapping clinical features)
CBS-AD from CBS due to primary tauopathies
CBS with Lewy body pathology from other subtypes
Disease Monitoring
NfL trajectories can predict progression
Biomarker changes over time may reflect treatment response
Useful for clinical trial endpoint selection
Treatment Stratification
Aβ42/Aβ40 ratio guides anti-amyloid therapy decisions
Biomarker profiles help select patients for targeted trials
Studies show good correlation between plasma and CSF biomarkers for:
p-tau181 (moderate correlation)
NfL (strong correlation)
Aβ42/Aβ40 (moderate correlation)
Plasma testing offers advantages in:
Patient accessibility
Repeated sampling
Cost-effectiveness
Prognostic Value
NfL as a Prognostic Marker
Neurofilament light chain (NfL) has emerged as a robust prognostic biomarker in atypical parkinsonian disorders:
Baseline NfL levels predict disease progression rate in both CBS and PSP [@plasma2025]
Longitudinal NfL trajectories correlate with clinical deterioration measured by standard rating scales (MDS-UPDRS, PSP rating scale)
Rapid progressors (defined by >10 points/year decline on MDS-UPDRS) show significantly higher baseline NfL compared to slow progressors
NfL doubling time of <6 months is associated with more aggressive disease phenotype
p-tau217 Prognostic Utility
Elevated p-tau217 in CBS patients predicts faster cognitive decline
Correlates with cortical tau burden on PET, which is associated with more severe dementia
May identify patients who would benefit from early anti-amyloid therapeutic intervention
p-tau181 Prognostic Value
Higher baseline p-tau181 levels associated with more rapid motor progression in PSP
Levels correlate with brain atrophy rates on serial MRI
GFAP as a Prognostic Marker
Elevated GFAP predicts faster disease progression in some studies
May reflect astrocyte-mediated neuroinflammatory component driving disease severity
Correlation with Disease Progression
Biomarker Trajectories Over Time
| Biomarker | Disease Stage | Expected Change | Clinical Correlation | |-----------|--------------|-----------------|----------------------| | NfL | Early → Advanced | 2-3x increase | Motor and cognitive decline | | p-tau217 | Early → Advanced | Progressive increase | Cortical tau spread | | p-tau181 | Early → Advanced | Moderate increase | Disease severity | | GFAP | Early → Advanced | Gradual increase | Neuroinflammation burden |
Imaging-Biomarker Correlations
NfL correlates with rates of cortical atrophy and white matter damage on MRI
p-tau217 correlates with cortical tau PET standardized uptake value ratios (SUVRs)
p-tau181 correlates with both cortical and subcortical tau deposition
GFAP correlates with regional brain hypometabolism on FDG-PET
Clinical-Biomarker Correlations
Higher baseline NfL predicts earlier loss of ambulation in PSP
Elevated p-tau217/p-tau181 correlates with earlier onset of cognitive impairment
Combined biomarker profiles can stratify patients into distinct progression phenotypes
Plasma vs CSF Biomarker Comparison
Biomarker Correlation Coefficients
| Biomarker | Plasma-CSF Correlation | Clinical Implication | |-----------|------------------------|---------------------| | NfL | r = 0.75-0.85 | Strong — plasma NfL reliably reflects CSF levels | | p-tau181 | r = 0.50-0.65 | Moderate — both useful but not interchangeable | | p-tau217 | r = 0.55-0.70 | Moderate — good for screening but CSF more precise | | Aβ42/Aβ40 | r = 0.45-0.60 | Moderate — ratio more consistent than absolute values | | GFAP | r = 0.40-0.55 | Moderate — plasma GFAP captures different pool |
Advantages of Plasma Testing
Accessibility: Blood draws are less invasive than lumbar punctures
Repeated sampling: Enables longitudinal monitoring and clinical trial visits
Cost-effectiveness: Lower procedure costs and infrastructure requirements
Patient acceptance: Higher willingness for blood-based testing vs CSF collection
Standardization: Easier to implement in routine clinical practice
Advantages of CSF Testing
Direct CNS reflection: CSF more directly reflects brain interstitial fluid
Lower peripheral interference: Reduced contamination from peripheral sources
Established reference ranges: More clinical validation data available
Better for α-synuclein SAA: Higher sensitivity for seed amplification assays
TDP-43 biomarkers: Currently only measurable in CSF
Clinical Implementation Recommendations
Initial diagnostic workup: Plasma biomarkers for broad screening
Confirmatory testing: CSF collection when plasma results are equivocal
Disease monitoring: Plasma NfL for longitudinal tracking
Clinical trials: Plasma for enrollment; CSF for mechanistic biomarkers
Clinical Implementation Guidelines
p-tau217 Cutoff Values for Differential Diagnosis
The following cutoff values are derived from published studies using the Fujirebio Lumipulse and Simoa platforms. Different assays have platform-specific thresholds; these values should be interpreted using the reference ranges provided by the testing laboratory.
| Condition | p-tau217 (Lumipulse) | p-tau217 (Simoa) | Interpretation | |-----------|---------------------|---------------------|-----------------| | Control | < 0.4 pg/mL | < 8.0 pg/mL | Normal range | | AD | > 0.8 pg/mL | > 15.0 pg/mL | Elevated — supports AD biology | | PSP | 0.4-0.7 pg/mL | 8.0-12.0 pg/mL | Borderline — may indicate pure 4R tauopathy | | CBS (non-AD) | 0.4-0.7 pg/mL | 8.0-12.0 pg/mL | Borderline — pure CBS without co-pathology | | CBS-AD | > 0.8 pg/mL | > 15.0 pg/mL | Elevated — suggests AD co-pathology |
Key clinical interpretation points:
AD vs. PSP differential: p-tau217 values > 0.8 pg/mL (Lumipulse) strongly favor AD co-pathology over pure PSP. Values in the 0.4-0.7 pg/mL range are typical for PSP and do not reliably exclude PSP when clinical features are present.
CBS subtyping: Elevated p-tau217 (> 0.8 pg/mL) in a CBS patient suggests underlying AD co-pathology, which may influence treatment decisions (e.g., anti-amyloid therapy eligibility) and prognostic counseling.
Gray zone: Values between 0.6-0.8 pg/mL require clinical correlation with imaging and neuropsychological testing.
Reference Laboratory Comparison
Mayo Clinic Laboratories
Uses Simoa platform for plasma p-tau217
Reference range: < 8.0 pg/mL (cognitively normal controls)
Provides age-adjusted reference ranges for patients > 65 years
NACC (National Alzheimer's Coordinating Center)
Uses multiple platforms in biomarker harmonization studies
Published cross-platform conversion factors available